Drug-Induced Sweet Syndrome

2019 ◽  
Vol 7 (7) ◽  
pp. 2400-2401 ◽  
Author(s):  
Mohammad Baseem Shaikh ◽  
Aleksander L. Krunic
Keyword(s):  
Drug Induced ◽  
Sweet Syndrome

scholarly journals Sweet Presentation of a Bitter Disease: Acute Febrile Neutrophilic Dermatosis Associated with Coccidioidomycoses

2021 ◽  
Vol 5 (2) ◽  
pp. 174-177
Author(s):  
Zainab Jafri ◽  
Lydia Shedlofsky ◽  
Andrew Newman ◽  
Travis Lam ◽  
Yebabe Mengesha
Keyword(s):  
Respiratory Infections ◽  
The United States ◽  
Neutrophilic Dermatosis ◽  
Inflammatory Disorder ◽  
Viral Gastroenteritis ◽  
Drug Induced ◽  
Sweet Syndrome ◽  
Acute Febrile Neutrophilic Dermatosis ◽  
Exact Etiology ◽  
Upper Respiratory

Acute Febrile Neutrophilic Dermatosis, also known as Sweet Syndrome, is an uncommon inflammatory disorder. Though the exact etiology is unclear, it has been presented in association with various entities. The majority of cases present following upper respiratory infections or viral gastroenteritis. Other causes include drug-induced reactions, pregnancy-related manifestations, or in association with specific hematologic or solid tumors. Rarely, it has been associated with Coccidioidomycosis, a prevalent fungus endemic to the Southwestern regions of the United States with a literature review revealing only three previous cases of Coccidioidomycosis-associated Sweet Syndrome. Here we report two new cases in individuals residing in Arizona.

Linezolid-Induced Reversible Posterior Leukoencephalopathy Syndrome; Fatal Pulmonary Toxicity after One Dose of Cyclophosphamide; Psychosis following Initiation of Zonisamide; Syndrome of Inappropriate Antidiuresis; Review of Rashes Associated with Antiepileptic Drugs; Review of Drug-Induced Sweet Syndrome

2007 ◽  
Vol 42 (7) ◽  
pp. 600-603 ◽  
Author(s):  
Joel Shuster
Keyword(s):  
Antiepileptic Drugs ◽  
Adverse Drug Reactions ◽  
Pulmonary Toxicity ◽  
Reversible Posterior Leukoencephalopathy Syndrome ◽  
Drug Reactions ◽  
Drug Induced ◽  
Sweet Syndrome ◽  
Reversible Posterior Leukoencephalopathy ◽  
Posterior Leukoencephalopathy ◽  
Inappropriate Antidiuresis

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the Food and Drug Administration's (FDA) medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML

2021 ◽  
Vol 14 (8) ◽  
pp. e243615
Author(s):  
Samer Alkassis ◽  
Aliza Rizwan ◽  
Lina Daoud ◽  
Jie Chi
Keyword(s):  
Myeloid Leukemia ◽  
Tandem Duplication ◽  
Neutrophilic Dermatosis ◽  
Neutrophilic Infiltration ◽  
Drug Induced ◽  
Internal Tandem Duplication ◽  
Sweet Syndrome ◽  
Acute Febrile Neutrophilic Dermatosis ◽  
Neutropenic Patients ◽  
Flt3 Internal Tandem Duplication

Sweet syndrome (SS), also referred as acute febrile neutrophilic dermatosis, is an inflammatory process characterised by the abrupt appearance of erythematous papules or nodules with predominant neutrophilic infiltration in the dermis. Fever and neutrophilia are common presenting features. However, extracellular manifestations, including ocular and musculoskeletal, may occur. SS is divided into three subtypes: classical (or idiopathic), malignancy associated and drug induced. Medication-induced subtype accounts for up to 26% of cases. In recent years, emerging evidence has showed that SS may also occur in neutropenic patients who underwent induction for acute myeloid leukemia (AML). The identification of FMS-like tyrosine kinase 3 (FLT3) gene mutation in approximately 30% of patients with AML has promoted the targeted therapy with FLT3-internal tandem duplication (ITD) inhibitors. Midostaurin, a recently Food and Drug Administration-approved medication for FLT3-ITD-positive AML, was reported once as cause for SS. We report a midostaurin-induced SS with neutropenia in a patient following induction chemotherapy of AML

Dermpath Clinic: Drug-induced Sweet syndrome

2016 ◽  
Vol 26 (6) ◽  
pp. 641-642 ◽  
Author(s):  
Pauline Hoelt ◽  
Kinda Fattouh ◽  
Axel-Patrice Villani
Keyword(s):  
Drug Induced ◽  
Sweet Syndrome

scholarly journals Drug-Induced Bullous Sweet Syndrome with Multiple Autoimmune Features

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Jared J. Lund ◽  
Erik J. Stratman ◽  
Deepa Jose ◽  
Ling Xia ◽  
Deborah Wilson ◽  
...  
Keyword(s):  
Relapsing Polychondritis ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Neutrophilic Dermatosis ◽  
Drug Induced ◽  
Sweet Syndrome ◽  
Mucosal Involvement ◽  
Acute Febrile Neutrophilic Dermatosis ◽  
Collagen Antibodies ◽  
Autoimmune Phenomena

Sweet syndrome (SS) (Acute Febrile Neutrophilic Dermatosis) has been reported in association with autoimmune phenomena including relapsing polychondritis, drug-induced lupus, and the development of antineutrophil cytoplasmic antibodies (ANCAs). However, a combination of these autoimmune features has not been reported. Herein, we report a case of drug-induced bullous SS with ocular and mucosal involvement, glomerulonephritis, and multiple autoimmune features including clinical polychondritis with antitype II collagen antibodies, ANCAs, antinuclear (HEp-2), and antihistone antibodies in a patient on hydralazine and carbamazepine.

Drug-Induced Sweet Syndrome in a Man With Sarcoidosis

2018 ◽  
pp. 1 ◽  
Author(s):  
Elena Gkrouzman ◽  
Lisa Chirch ◽  
Santhanam Lakshminarayanan
Keyword(s):  
Drug Induced ◽  
Sweet Syndrome

scholarly journals Sweet syndrome: a sweet disease with a bitter diagnosis

2018 ◽  
Vol 6 (8) ◽  
pp. 2863
Author(s):  
Eswar Ganti ◽  
Shalima Pinnamaneni ◽  
Santhosh Kumar A. ◽  
Syam Venkat K.
Keyword(s):  
Diagnostic Criteria ◽  
Lupus Erythematosus ◽  
Skin Lesions ◽  
The Body ◽  
Neutrophilic Dermatosis ◽  
Drug Induced ◽  
Sweet Syndrome ◽  
Superficial Skin ◽  
Chief Complaints ◽  
Acute Febrile Neutrophilic Dermatosis

Sweet syndrome is an acute febrile neutrophilic dermatosis first described by Robert Douglas Sweet in 1964. Sweet syndrome presents in three clinical settings: classical (or idiopathic), malignancy-associated, and drug-induced. It has been associated with hematopoietic malignancies and myelodysplastic disorders. A-28-years married woman presented to us with chief complaints of Fever and Multiple swellings over the body since 2 months. At presentation she has Pallor; venous hum present. Multiple, tender, erythematous subcutaneous swellings, firm in consistency noted in both forearms. Skin over the swellings is pinchable; superficial skin is normal. Sweet syndrome can occasionally cause an intense systemic response involving the lungs, liver and musculoskeletal system. The skin lesions in Sweet syndrome typically start as erythematous papules, plaques, and nodules. The lesions can take on pseudovesicular or pseudopustular appearance, and sometimes fully formed vesicles or pustules develop. The lesions can be subcutaneous mimicking erythema nodosum which can’t be differentiated unless a biopsy is taken. Because the diagnosis of Sweet syndrome can be challenging, particularly when associated with other connective tissue disorders such as SLE, a set of diagnostic criteria were proposed initially by Su and Liu and then revised by Von den Driesch. The diagnosis is based upon the presence of two major and two of the four minor criteria. Concurrent Sweet syndrome and SLE are exceedingly rare. Twelve patients with both Sweet syndrome and systemic lupus erythematosus (SLE) have been previously reported. We report a case of sweet syndrome associated with SLE diagnosed in our hospital. In our patient, diagnostic criteria are satisfied for Sweet syndrome as well as for SLE (ACR criteria-patient had polyarthralgia, anemia, thrombocytopenia, ANA and Ds DNA positive. Four out of 11 are fulfilled for SLE). Patient responded to corticosteroids.

Sweet Syndrome: Clinical Features, Histopathology, and Associations of 83 Cases

2017 ◽  
Vol 21 (3) ◽  
pp. 211-216 ◽  
Author(s):  
Jose Ricardo Casarin Costa ◽  
Anangelica Rodrigues Virgens ◽  
Luisa de Oliveira Mestre ◽  
Natasha Favoretto Dias ◽  
Luciana Paula Samorano ◽  
...  
Keyword(s):  
Histopathological Examination ◽  
Age At Onset ◽  
Sudden Onset ◽  
Drug Induced ◽  
Recent Infection ◽  
Sweet Syndrome ◽  
Potential Marker ◽  
Choice Of Treatment ◽  
The Mean ◽  
Erythematous Plaques

Background: Sweet syndrome (SS) is an infrequent skin disease characterised by sudden onset of fever, leukocytosis, neutrophilia, and tender erythematous plaques infiltrated by neutrophils. Multiple conditions have been associated with this syndrome. Objectives: The aim of this study was to evaluate the clinical, epidemiological, laboratory, and histopathological findings and associations of patients with SS. Methods: We conducted a retrospective study of 83 patients with SS followed between January 1, 2006, and January 31, 2015. Results: Of the patients, 82% were female; the mean age at onset was 48 years. Clinical presentation was mainly characterised by erythematous and edematous plaques, mostly on upper extremities and trunk. Fever was observed in 32%; 60% presented leukocytosis and 39% neutrophilia. On histopathological examination, neutrophilic and lymphohistiocytic infiltrate and edema were the most frequent findings. Fourteen percent of patients had malignancy or hematologic disorders, 26% were classified as having drug-induced SS, and 24% noted recent infection. Only 2 cases occurred during pregnancy. Systemic corticosteroid was the most common choice of treatment, with excellent response. In malignancy-associated SS, the mean hemoglobin level was lower ( P = .01) and the erythrocyte sedimentation rate (ESR) was higher ( P = .04) in comparison to classic and drug-induced SS. Leukocytoclasia was associated with higher risk of recurrence ( P = .01). Conclusion: All patients with SS deserve careful investigation of possible underlying conditions. Higher ESR and lower hemoglobin levels might reinforce the need of malignancy screening. Also, leukocytoclasia appears to be a potential marker of higher recurrence rate, demanding closer and longer follow-up.

Drug-Induced Sweet Syndrome in a Man With Sarcoidosis

2019 ◽  
Vol 25 (7) ◽  
pp. e122-e126
Author(s):  
Elena Gkrouzman ◽  
Lisa Chirch ◽  
Santhanam Lakshminarayanan
Keyword(s):  
Drug Induced ◽  
Sweet Syndrome
Sign in / Sign up

Export Citation Format

Share Document